results pretty goodTough year to be moving operations (across country). Appears that Covid socked it to them in the 2nd half results. However, with the dust settling on operations will be watching for the uptrend now. I know most are looking at the business development side but I would like to see them continue to grow the foundation they have as cash flow appears good and it supports the bells and whistles.
Regarding development seems like not too much action or clarity. Hard to get a sense of progress. Will knock them on that.
It is nice to see a small cap "kind of biotech" that is able to pay its way and has a business. Its a competitive world and if they hope to reach the next level they have to get way more aggressive.